# Safety, Tolerability, Pharmacokinetic Characteristics of hzVSF-v13 in Healthy Male Volunteers

> **NCT03653208** · PHASE1 · COMPLETED · sponsor: **ImmuneMed, Inc.** · enrollment: 56 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** hzVSF-v13
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03653208
- **Lead sponsor:** ImmuneMed, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-20
- **Primary completion:** 2020-02-29
- **Final completion:** 2020-02-29
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2021-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03653208

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03653208, "Safety, Tolerability, Pharmacokinetic Characteristics of hzVSF-v13 in Healthy Male Volunteers". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT03653208. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*